Evofem licenses Phexxi to Pharma 1 for Middle East; closes $500K private placement with Aditxt

Evofem Biosciences, Inc.

Exclusive 5-year license for Phexxi in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.
Pharma 1 to file UAE regulatory submission in Q3 2024; UAE contraceptive market projected $185.1M by 2030.
Pharma 1 pays cost-to-manufacture plus fee; must maintain at least 4 months of inventory at all times.
Evofem closed $500K private placement with Aditxt via 500 shares of Series F-1 Preferred Stock.
Merger with Aditxt targeting September 30, 2024 closing; amended merger agreement dated July 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.